Brolucizumab demonstrates drying effect in patients with DME

In this video from Hawaiian Eye, Rishi P. Singh, MD, discusses results from the KITE and KESTREL trials of brolucizumab vs. aflibercept in the treatment of diabetic macular edema.
The 52-week endpoint results, recently presented at the virtual Association for Research in Vision and Ophthalmology meeting, showed a higher proportion of patients with fluid resolution in the brolucizumab (Beovu, Novartis) arm than the aflibercept (Eylea, Regeneron) arm.
See more ophthalmology news and videos at www.healio.com...